Pamicell Re-certified as an Innovative Pharmaceutical Company

[Asia Economy Reporter Hyungsoo Park] Pharmicell announced on the 1st that it has successfully renewed its certification as an innovative pharmaceutical company selected by the Ministry of Health and Welfare, and the certification will be valid for three years until 2025.

The innovative pharmaceutical company program supports pharmaceutical companies with research and development capabilities and global market entry potential by providing benefits such as ▲ preferential drug pricing ▲ R&D incentives ▲ tax support ▲ regulatory relaxation ▲ workforce support.

Pharmicell was first selected in 2016, renewed in 2019, and completed re-certification again this year. It has successfully maintained its status as an innovative pharmaceutical company for three consecutive terms. Through this, it plans to accelerate research and development of stem cell therapies and pharmaceutical raw materials.

A Pharmicell official stated, "We have invested about 20% of our sales in research and development over the past three years," adding, "We will continue to actively invest not only in stem cell therapies but also in nucleoside research, which is a raw material for RNA therapies."

Pharmicell's bio business division is conducting clinical trials of autologous stem cell therapies such as Cellgram-LC (for alcoholic liver cirrhosis treatment), Cellgram-ED (for erectile dysfunction treatment), allogeneic stem cell therapy Cellgram-CKD (for chronic kidney disease treatment), along with a cancer immunotherapy vaccine using dendritic cells.

The chemical business division is developing and producing nucleosides used in mRNA vaccines and RNA therapies, as well as dNTP, a key material for PCR testing, and mPEG, a drug delivery material.